- Approved indication
- Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
- Route
- Subcutaneous injection once daily
- Dose
- 1.4 mg (EGRIFTA SV) or 2.0 mg (original EGRIFTA) once daily
- Frequency
- Once daily into abdomen
- EGRIFTA SV is formulated at 2 mg per vial reconstituted to 1.4 mg/0.35 mL.
- Label explicitly states it is not indicated for general weight loss.
